LENZ Therapeutics Reports Third Quarter Revenue and EPS Miss
LENZ Therapeutics reported third-quarter financial results that fell short of market expectations. The company posted a GAAP earnings per share (EPS) of -$0.99, missing estimates by $0.04. Revenue for the quarter was $3.38 million, representing a significant 73% year-over-year decline and missing consensus estimates by $0.82 million. The results reflect ongoing volatility as the company continues its clinical and commercial development phases.
Tickers: $LENZ
Topics: EPS miss quarterly earnings revenue miss